Neuroscience & Biobehavioral Reviews, Journal Year: 2023, Volume and Issue: 146, P. 105035 - 105035
Published: Jan. 3, 2023
Language: Английский
Citations
16Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA™, Ella™, and Lumipulse™ in multiple sclerosis naïve patients.
Multiple Sclerosis and Related Disorders, Journal Year: 2023, Volume and Issue: 82, P. 105412 - 105412
Published: Dec. 26, 2023
BACKGROUNDNeurofilament light chains (NfL) are cytoskeletal biomarkers of axonal damage, about 40-fold higher in cerebrospinal fluid (CSF) compared to serum, and requiring ultrasensitive techniques be measured this latter fluid.OBJECTIVESTo compare CSF serum NfL levels multiple sclerosis (MS) patients using different platforms.METHODS60 newly diagnosed relapsing-remitting MS (38 females; median age: 36.5 years, range: 15-60) were enrolled before steroid or disease-modifying treatments. with: the commercial Ella™ microfluidic platform (Bio-Techne), Lumipulse™ Chemiluminescent Enzyme ImmunoAssay (Fujirebio), SIMOA™ on SR-X instrument NF-light assays (Quanterix).RESULTSCSF absolute strongly correlated between assays, although being more elevated with Ella™. Passing-Bablok regression showed high agreement measuring (with greater proportional difference Ella™), very for comparing Lumipulse™. Similarly, Bland-Altman comparison evidenced lower biases both fluids.CONCLUSIONSCSF naïve reliably all assays. Although not interchangeable, values.
Language: Английский
Citations
16Emerging Trends: Neurofilament Biomarkers in Precision Neurology
Neurochemical Research, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 30, 2024
Language: Английский
Citations
5Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide
Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13
Published: Sept. 27, 2022
The clinical course of multiple sclerosis (MS) is highly variable among patients, thus creating important challenges for the neurologist to appropriately treat and monitor patient progress. Despite some patients having apparently similar symptom severity at MS disease onset, their prognoses may differ greatly. To this end, we believe that a proactive disposition on part identify prognostic “red flags” early in can lead much better long-term outcomes terms reduced disability improved quality life. Here, present prognosis tool form checklist clinical, imaging biomarker parameters which, based consensus literature our own experiences, have established be associated with poorer or outcomes. encouraged use presence absence specific variables individual onset thereby implement sufficiently effective treatment strategies address likely each patient.
Language: Английский
Citations
20No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients
Biomolecules, Journal Year: 2025, Volume and Issue: 15(1), P. 68 - 68
Published: Jan. 6, 2025
Despite significant efforts, there is still an existing need to identify diagnostic tools that would enable fast and reliable detection of the progressive stage multiple sclerosis (MS) help in monitoring disease course and/or treatment effects. The aim this prospective study a group people with MS was determine whether changes levels selected serum biomarkers cognitive function may predict progression, therefore refine decision-making process evaluation patients. Forty two (42) patients completed all procedures; mean duration follow-up 12.97 months. During observation period, concentration chitinase-3 like-protein-1 (CHI3L1/YKL-40) decreased significantly whole (from 4034.95 ± 262.62 2866.43 173.37; p = 0.0005), as well subgroups secondary primary (SPMS: from 3693.81 388.68 2542.76 256.59; 0.0207; PPMS: 4376.09 353.27 3190.09 233.22; 0.0089, respectively). A worsening Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) scores detected 1.18 0.14 1.34 0.15; 0.0331) PPMS subgroup 1.04 0.18 1.26 0.20; 0.0216). No correlations between analyzed molecular parameters or results neuropsychological tests physical disability were observed. In conclusion, emphasis should be placed on furthering search multimodal especially PMS population, based simultaneous analysis several factors, such blood profiles.
Language: Английский
Citations
0The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications.
eNeurologicalSci, Journal Year: 2025, Volume and Issue: 38, P. 100550 - 100550
Published: Jan. 6, 2025
Fluid biomarkers such as Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light (NfL) play important roles in the diagnosis, monitoring, evaluation of therapeutic responses conditions Multiple Sclerosis (MS) Aquaporin-4 Neuromyelitis Optica Spectrum Disorder (AQP4-NMOSD). These offer key insights into underlying pathophysiological mechanisms these diseases, enabling effective follow-up personalized treatment approaches, which are essential for improving patient outcomes. Herein, we synthesize structural attributes, functional roles, clinical significance GFAP NfL context MS AQP4-NMOSD. We explore critical implications disease manifestation progression, emphasizing necessity to develop standardized methodologies multicentric studies confirm their applicability.
Language: Английский
Citations
0Establishing Decisional Cutoff Values of Neurofilament Light Chains in Cerebrospinal Fluid Measured by Fully Automated Chemiluminescent Enzyme Immunoassay
Journal of Clinical Laboratory Analysis, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 15, 2025
Neurofilament light chain (NfL) is one of the most important biomarkers in field clinical neurochemistry. Several analytical methods have been developed last decade. Recently, Fujirebio introduced a ready-to-use assay kit for measuring NfL levels cerebrospinal fluid (CSF) on fully automated LUMIPULSE G System. In this study, we established decisional cutoffs CSF NfL. We performed retrospective observational study including patients with cognitive decline. were measured by two methods: NF-light ELISA (UmanDiagnostics) and Lumipulse G1200 system (Fujirebio). calculated Lumipulse, starting from consolidated method each age using equation obtained regression analysis. The population consisted 100 median 776.5 ± 772.6 pg/mL 473.5 443.5 pg/mL, respectively, significantly different (p < 0.001). Spearman's rank correlation coefficient was 0.962, indicating robust positive between measurement methods. derived Passing-Bablok analysis CLEIA = -61.16 + 1.83 × ELISA. Based equation, defined cutoff values. Decisional are fundamental tools guiding clinicians to use biomarkers' results interpretation appropriately. This first establishing value platform widely used laboratories.
Language: Английский
Citations
0A real-world data of serum neurofilament light chain in a large cohort of Egyptian multiple sclerosis patients: Hospital-based study
Multiple Sclerosis and Related Disorders, Journal Year: 2025, Volume and Issue: 94, P. 106286 - 106286
Published: Jan. 22, 2025
Language: Английский
Citations
0Circulating cell-free DNA methylation profiles as noninvasive multiple sclerosis biomarkers: A proof-of-concept study
medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 20, 2025
Abstract In multiple sclerosis (MS), there is a critical need for non-invasive biomarkers to concurrently classify disease subtypes, evaluate disability severity, and predict long-term progression. this proof-of-concept study, we performed low-coverage whole-genome bisulfite sequencing (WGBS) on 75 plasma cell-free DNA (cfDNA) samples assessed the clinical utility of cfDNA methylation as single assay distinguishing MS patients from non-MS controls, identifying estimating predicting trajectories. We identified thousands differentially methylated CpGs hundreds regions (DMRs) that significantly distinguished separated stratified severity levels. These DMRs were highly enriched in immunologically neurologically relevant regulatory elements ( e.g., active promoters enhancers) contained motifs associated with neuronal function T-cell differentiation. To distinguish subtypes groups, achieved area-under-the-curve (AUC) values ranging 0.67 0.81 using 0.70 0.82 inferred tissue-of-origin patterns methylation, outperforming benchmark neurofilament light chain (NfL) glial fibrillary acidic protein (GFAP) same cohort. Finally, linear mixed-effects model “prognostic regions” where baseline levels progression predicted future (AUC=0.81) within 4-year evaluation window. As plan generate higher-depth WGBS data validation independent cohorts, present findings suggest potential circulating profiles promising noninvasive diagnosis prognosis.
Language: Английский
Citations
0High efficacy therapy to prevent the formation of meningeal tertiary lymphoid organs after CXCL13 index screening in early multiple sclerosis
Frontiers in Neuroscience, Journal Year: 2025, Volume and Issue: 19
Published: March 17, 2025
Postmortem studies have shown the presence of subpial inflammation with tertiary lymphoid organs (TLO) in meninges patients progressive multiple sclerosis, playing an important role pathophysiology disease. The chemokine (C-X-C motif) ligand 13 (CXCL13) induces formation these organs, thus promoting activity progression to disability sclerosis has been reduced, thanks effect disease modifying therapy. However, despite advances treatment immunomodulatory agents, we still lack specific laboratory biomarkers that could indicate state disease, either at time diagnosis or when escalation therapy seems be mandatory. In MRI not demonstrated TLO CNS, so far. determination CXCL13 index (ICXCL 13), clinical specimens, become a reliable biomarker for verification and TLO, contributing improving outcome, high efficacy therapy, setting.
Language: Английский
Citations
0